Analysts predict Elevance Health’s Q4 earnings will decline, with revenue growth expected
Interestingly, the earnings estimate has been slightly adjusted down by 0.1% over the past month. This shows that analysts have been rethinking their predictions as the report date approaches. It’s always good to keep an eye on these changes since they can hint at how investors might react.
Now, let’s break down some of the key metrics analysts are watching. For instance, they expect ‘Revenues- Premiums’ to reach $36.61 billion, which is a 4.2% increase from last year. Meanwhile, ‘Revenues- Service fees’ are estimated at $2.09 billion, showing an 8.6% rise.
When it comes to ‘Revenues- Net investment income,’ analysts predict it will be around $532.37 million, a slight 0.6% increase. For ‘Revenues- Product revenue,’ the estimate is $5.94 billion, reflecting a 10.2% growth.
On the membership side, analysts expect ‘Medical Membership – Total’ to be about 45.98 million, down from 46.96 million last year. For ‘Medical Membership – Medicare – Medicare Advantage,’ the estimate is 2.05 million, unchanged from last year.
Looking at ‘Medical Membership – Medicaid,’ the estimate is 9.06 million, down from 10.5 million. For ‘Medical Membership – Federal Employees Health Benefits,’ they expect 1.66 million, a slight increase from last year’s 1.64 million.
The total for ‘Medical Membership – Total Medicare’ is estimated at 2.94 million, down from 2.97 million last year. Analysts also predict ‘Medical Membership – Commercial Risk-Based – Individual’ will reach 1.32 million, up from 1.03 million last year.
Lastly, the ‘Benefit Expense Ratio’ is expected to be 92.4%, compared to 89.2% last year. The ‘Medical Membership – Commercial Fee-Based’ is projected at 27.33 million, slightly up from 27.07 million last year.
In the past month, Elevance Health’s shares have risen by 5.1%, while the S&P 500 has dipped by 2.1%. With a Zacks Rank of #3 (Hold), it looks like ELV will follow the market’s lead for now. If you’re curious about more top stocks, Zacks has a list of their top picks for 2025 that you might want to check out.
